Multiply Labs
San Francisco maker of robotic systems that automate GMP manufacturing of cell and gene therapies and other biologics.
- Robotics funding from mid-September to mid-October 2026: chips, data and safety took the private money while humanoid makers turned to stock markets
In the 30 days to October 14, 2026, MEKAWIRE verified 14 private robotics rounds with disclosed amounts worth $1,071.3 million. Compute chips took 51.3%, robot models 20.5% and data, perception and safety software 8.7%, while humanoid makers received $10 million, or 0.9%, against 13.4% between January and mid-September. The four October rounds, Mecka, Multiply Labs, SafeWorld and Minerva Humanoids, paid for what stands between a capable robot and a paid deployment, while humanoid makers raised through an IPO, a SPAC and a Form D offering.
Subject - Mecka's $60 million Series B: Sequoia, NVIDIA and Samsung back a robot-data supplier claiming a $100 million revenue run rate
Mecka said in a company post dated Oct 7 that it raised a $60 million Series B led by Sequoia Capital, with NVIDIA, M12, Qualcomm Ventures and Samsung joining and Kindred, Framework Ventures and Neo returning. The company, which records human demonstrations with its own sensor rigs and sells the data and post-trained models, says it passed a $100 million revenue run rate in June and aims for $300 million by year end.
Mentioned - Multiply Labs raises $75 million led by Patrick Soon-Shiong to scale robots that make cell and gene therapies
Multiply Labs said in a press release on Oct 6 that it raised a $75 million Series B led by Patrick Soon-Shiong, with AstraZeneca, Lingotto, Teradyne and Strange Ventures joining as new investors. The San Francisco company, which automates GMP manufacturing of cell and gene therapies, said total funding now exceeds $100 million and the money goes to manufacturing capacity, product work and engineering, regulatory and commercial hiring.
Subject